VRM
BMY.RT

Vectors Research Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Vectors Research Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-400
Closed – – 491
2020
Q4 		$0 Hold
400
– – ﹤0.01% 494
2020
Q3 		$1K Hold
400
– – ﹤0.01% 424
2020
Q2 		$1K Hold
400
– – ﹤0.01% 436
2020
Q1 		$2K Buy
+400
New +$1.32K ﹤0.01% 445

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Vectors Research Management's BMY.RT Position: Q1 2021 in Review

Vectors Research Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 400 shares.

Vectors Research Management first reported a position in BMY.RT in Q1 2020 and held it in 4 quarters. The position peaked at $2K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Vectors Research Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Vectors Research Management sold 400 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Vectors Research Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 4 quarters.
  • Vectors Research Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $2K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Vectors Research Management's 13F filing for Q1 2021, filed 18 May 2021.